Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 19, Pages 10822
Publisher
MDPI AG
Online
2021-10-08
DOI
10.3390/ijms221910822
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
- (2021) Narjes Nasiri-Ansari et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis
- (2021) Shimaa K. Elkazzaz et al. LIFE SCIENCES
- Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells
- (2021) Nawel Zaibi et al. PLoS One
- Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
- (2021) Christian Hölscher BRITISH JOURNAL OF PHARMACOLOGY
- Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect of gliflozins
- (2021) Sin-Hee Park et al. Cardiovascular Diabetology
- Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
- (2021) Kana N. Miyata et al. CLINICAL SCIENCE
- Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials
- (2021) Jonathan J. H. Bray et al. DIABETES OBESITY & METABOLISM
- A sweet spot for macrophages: Focusing on polarization
- (2021) Depeng Yang et al. PHARMACOLOGICAL RESEARCH
- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
- (2021) Zien Zhou et al. STROKE
- Mechanism and application of metformin in kidney diseases: An update
- (2021) Anni Song et al. BIOMEDICINE & PHARMACOTHERAPY
- SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction
- (2021) Ahmed S. Ahmed et al. BIOMEDICINE & PHARMACOTHERAPY
- Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease
- (2021) Ferdinando Carlo Sasso et al. Cardiovascular Diabetology
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- The role of incretins and incretin-based drugs in autoimmune diseases
- (2021) Shabnam Radbakhsh et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment
- (2021) Yaoyun Niu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Non-Coding RNAs in Kidney Diseases: The Long and Short of Them
- (2021) Juan Antonio Moreno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
- (2021) Giuseppe Palmiero et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats
- (2021) Jingjing Tian et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Empagliflozin and neohesperidin mitigate methotrexate hepatotoxicity via Nrf2/PPARγ/HO-1 signalling initiation and suppression of NF-κB/Keap1/HSP70/caspase-3 axis in rats
- (2021) Adel T. Osman et al. LIFE SCIENCES
- Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
- (2021) Francesco Prattichizzo et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study
- (2021) Diana Nabrdalik-Leśniak et al. Oxidative Medicine and Cellular Longevity
- Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
- (2021) Nami Lee et al. Journal of Immunology Research
- Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
- (2021) Sanjay Kalra et al. Diabetes Therapy
- Safety of Semaglutide
- (2021) Mark M. Smits et al. Frontiers in Endocrinology
- Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells
- (2021) Jing Xu et al. Cells
- Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
- (2021) Nunzia D'Onofrio et al. Molecular Metabolism
- Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Milton Packer AMERICAN JOURNAL OF NEPHROLOGY
- Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
- (2020) Nikole J. Byrne et al. Circulation-Heart Failure
- Interplay of adenosine monophosphate‐activated protein kinase/sirtuin‐1 activation and sodium influx inhibition mediates the renal benefits of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: A novel conceptual framework
- (2020) Milton Packer DIABETES OBESITY & METABOLISM
- Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation
- (2020) Shu Fang et al. Journal of Diabetes Research
- Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
- (2020) Milton Packer Cardiovascular Diabetology
- Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
- (2020) Detmar Kolijn et al. CARDIOVASCULAR RESEARCH
- Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
- (2020) Xiaodong Sun et al. DIABETES
- Recent advances in understanding the role of hypoxia-inducible factor 1α in renal fibrosis
- (2020) Xuejiao Wei et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
- (2020) Mehmet Kanbay et al. JOURNAL OF NEPHROLOGY
- Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors
- (2020) Milton Packer JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Guidelines and definitions for research on epithelial–mesenchymal transition
- (2020) Jing Yang et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Stimulation of GLP-1 Receptor Inhibits Methylglyoxal-Induced Mitochondrial Dysfunctions in H9c2 Cardiomyoblasts: Potential Role of Epac/PI3K/Akt Pathway
- (2020) Narawat Nuamnaichati et al. Frontiers in Pharmacology
- A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
- (2020) Jonathan J.H. Bray et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
- (2020) Chintan N. Koyani et al. PHARMACOLOGICAL RESEARCH
- Empagliflozin suppresses inflammation and protects against acute septic renal injury
- (2020) Zaid H. Maayah et al. INFLAMMOPHARMACOLOGY
- Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
- (2020) Angelamellisy Ndibalema et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
- (2020) Masaomi Nangaku et al. Kidney International Reports
- Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
- (2020) Laween Uthman et al. CARDIOVASCULAR DRUGS AND THERAPY
- Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors
- (2020) Milton Packer Circulation-Heart Failure
- Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
- (2020) Victor Okunrintemi et al. DIABETES OBESITY & METABOLISM
- Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver
- (2020) Mohammed Kh. ElMahdy et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
- (2020) Niki Katsiki et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats
- (2020) Rania G. Abdel-latif et al. LIFE SCIENCES
- Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice
- (2020) Amir Mohamed Abdelhamid et al. LIFE SCIENCES
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
- (2020) Raquibul Hasan et al. Scientific Reports
- Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK–Akt–eNOS pathway in the isoprenaline-induced oxidative stress model
- (2020) Raquibul Hasan et al. Scientific Reports
- New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis
- (2020) Lili Sheng et al. Frontiers in Physiology
- Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
- (2020) Riying Liang et al. Endocrine Connections
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- NRF2 in Cardiovascular Diseases: a Ray of Hope!
- (2020) Ruju Vashi et al. Journal of Cardiovascular Translational Research
- Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
- (2020) Amelia Charlton et al. Biology-Basel
- Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- (2020) John J.V. McMurray et al. CIRCULATION
- microRNA-665 silencing improves cardiac function in rats with heart failure through activation of the cAMP signaling pathway
- (2019) Bin Lin et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Endothelial to Mesenchymal Transition in Cardiovascular Disease
- (2019) Jason C. Kovacic et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
- (2019) Hiroe Nagaike et al. Diabetes Therapy
- Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
- (2019) Ajay Sood et al. Metabolic Syndrome and Related Disorders
- Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart
- (2019) Wei Ding et al. Frontiers in Endocrinology
- Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
- (2019) Keiichiro Matoba et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Liraglutide attenuates pre-established atherosclerosis in apolipoprotein E deficient mice via regulation of immune cell phenotypes and pro-inflammatory mediators
- (2019) Robyn Bruen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling
- (2019) Fengjuan Huang et al. Frontiers in Endocrinology
- Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice
- (2019) Tzu-Hsien Tsai et al. Cells
- Glucagon-like peptide-1 receptor pathway inhibits extracellular matrix production by mesangial cells through store-operated Ca2+ channel
- (2019) Linjing Huang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II–dependent kidney damage
- (2019) Humberto Reyes-Pardo et al. BMC Nephrology
- The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus
- (2019) Weiling Leng et al. Annals of Translational Medicine
- Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation
- (2019) Foteini Moschovaki Filippidou et al. AMERICAN JOURNAL OF PATHOLOGY
- Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
- (2019) Liang Xu et al. BMJ Open Diabetes Research & Care
- Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats
- (2019) Ruben Rodriguez et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
- (2019) Nitin A. Das et al. CELLULAR SIGNALLING
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
- (2018) Yochai Birnbaum et al. CARDIOVASCULAR DRUGS AND THERAPY
- The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
- (2018) Ya-Kun Li et al. PHARMACOLOGICAL RESEARCH
- Glucagon-Like Peptide-1 and its Cleavage Products are Renoprotective in Murine Diabetic Nephropathy
- (2018) Moellmann Julia et al. DIABETES
- MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer
- (2018) Xiaotian Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- (2017) Mohsen Mazidi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat
- (2017) Ya Zhang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
- (2017) Jui-Ting Chang et al. BMC Pharmacology & Toxicology
- Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway
- (2017) Anping Wang et al. PLoS One
- GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
- (2016) Qin He et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1
- (2016) Fen Xu et al. DIABETOLOGIA
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Warburg Effect: How Does it Benefit Cancer Cells?
- (2016) Maria V. Liberti et al. TRENDS IN BIOCHEMICAL SCIENCES
- Partial Epithelial-to-Mesenchymal Transition and Other New Mechanisms of Kidney Fibrosis
- (2016) Sara Lovisa et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice
- (2015) Serap Sancar-Bas et al. GROWTH FACTORS
- Unknown
- (2015) Fei Yan et al. MOLECULAR MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress
- (2015) Antonio Ceriello et al. Therapeutics and Clinical Risk Management
- Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
- (2014) Antonio Ceriello et al. DIABETES CARE
- Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
- (2013) A. Ceriello et al. DIABETES CARE
- Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus
- (2013) Andrew E. Hogan et al. DIABETOLOGIA
- Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
- (2013) Yen-Ta Chen et al. Journal of Translational Medicine
- The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
- (2013) Hiroki Fujita et al. KIDNEY INTERNATIONAL
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes
- (2013) Lan He et al. Journal of Diabetes Investigation
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
- (2010) I. Hadjiyanni et al. DIABETOLOGIA
- Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
- (2009) Le Thi Kim Chung et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now